Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael D Ezekowitz

Showing results (41-50 of 187) with videos related to

Pageof 19
Sort By:
Circulation|February 6, 2002
Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP studyLouis D Fiore, Michael D Ezekowitz, Mary T Brophy, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|March 26, 2011
Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trialMasatsugu Hori, Stuart J Connolly, Michael D Ezekowitz, et al.
Gender Medicine|July 20, 2010
Gender in atrial fibrillation: Ten years laterHector I Michelena, Brian D Powell, Peter A Brady, et al.
Clinical Cardiology|March 31, 2016
Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48Anna Plitt, Michael D Ezekowitz, Raffaele De Caterina, et al.
Circulation|September 10, 2009
The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillationDavid J Ellis, Mohammed Haris Usman, Peter G Milner, et al.
Journal of the American College of Cardiology|May 13, 2014
Reply: regarding the effect of dabigatran plasma concentrationsPaul A Reilly, Stuart J Connolly, Salim Yusuf, et al.
Cardiovascular Therapeutics|August 20, 2009
Secondary prevention in concurrent coronary artery, cerebrovascular, and chronic kidney disease: focus on pharmacological therapyLawrence A Notaro, Mohammed H Usman, James F Burke, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|June 15, 2021
Predictors of sinus rhythm 6 weeks after cardioversion of atrial fibrillation: a pre-planned post hoc analysis of the X-VeRT trialRiccardo Cappato, Michael D Ezekowitz, Stefan H Hohnloser, et al.
The American Journal of Cardiology|April 14, 2009
Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble?M Haris U Usman, Lawrence A Notaro, Rangadham Nagarakanti, et al.
European Heart Journal|March 15, 2013
Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)Stuart J Connolly, John Eikelboom, Paul Dorian, et al.
Pageof 19

Showing results (41-50 of 187) with videos related to

Sort By:
Pageof 19
Circulation|February 6, 2002
Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP studyLouis D Fiore, Michael D Ezekowitz, Mary T Brophy, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|March 26, 2011
Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trialMasatsugu Hori, Stuart J Connolly, Michael D Ezekowitz, et al.
Gender Medicine|July 20, 2010
Gender in atrial fibrillation: Ten years laterHector I Michelena, Brian D Powell, Peter A Brady, et al.
Clinical Cardiology|March 31, 2016
Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48Anna Plitt, Michael D Ezekowitz, Raffaele De Caterina, et al.
Circulation|September 10, 2009
The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillationDavid J Ellis, Mohammed Haris Usman, Peter G Milner, et al.
Journal of the American College of Cardiology|May 13, 2014
Reply: regarding the effect of dabigatran plasma concentrationsPaul A Reilly, Stuart J Connolly, Salim Yusuf, et al.
Cardiovascular Therapeutics|August 20, 2009
Secondary prevention in concurrent coronary artery, cerebrovascular, and chronic kidney disease: focus on pharmacological therapyLawrence A Notaro, Mohammed H Usman, James F Burke, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|June 15, 2021
Predictors of sinus rhythm 6 weeks after cardioversion of atrial fibrillation: a pre-planned post hoc analysis of the X-VeRT trialRiccardo Cappato, Michael D Ezekowitz, Stefan H Hohnloser, et al.
The American Journal of Cardiology|April 14, 2009
Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble?M Haris U Usman, Lawrence A Notaro, Rangadham Nagarakanti, et al.
European Heart Journal|March 15, 2013
Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)Stuart J Connolly, John Eikelboom, Paul Dorian, et al.
Pageof 19